

Supporting Information

Catalyst-Free Three-Component Synthesis of Highly Functionalized 2,3-Dihydropyrroles

Dong Wang, Linna Li, Hairong Feng, Hua Sun, Fabrice Almeida-Veloso, Marine Charavin, Peng Yu, and Laurent Désaubry*

Table of Contents

1. General Experimental.....	SI-2
2. Preparation Procedure for 3, 4, 5 and 6	SI-3
3. Mechanism studies.....	SI-24
4. ORTEP Drawing for 4o	SI-27
5. NOESY for 4a.....	SI-27
6. Kinetics of α -Glucosidase Inhibition	SI-28
7. Reference.....	SI-29
8. Spectra Data.....	SI-29

1. General Experimental

The preparation experiments were performed under an argon atmosphere in oven dried glassware. Solvents used as reaction media were distilled immediately before use: THF and ether were distilled from Na/benzophenone ketyl, dichloromethane was distilled from calcium hydride, DMF was obtained from vacuum distillation, EtOH was distilled from Mg and I₂. All reagents were purchased at the highest commercial quality and used without further purification. Reactions were monitored by thin layer chromatography (TLC) using ultra violet light (UV) as the visualizing agent. Nuclear magnetic resonance spectra (NMR) were recorded on Bruker AV-400 instruments and were calibrated using residual undeuterated solvent as an internal reference (¹H NMR: CHCl₃ 7.26 ppm, MeOH 3.31 ppm). The following abbreviations were used to indicate multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, qui = quintet, sxt = sextet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, ddt = doublet of doublet of triplets, m = multiplet).

General Procedure A: Preparation of pyruvic amides (3)


To a solution of pyruvic acid (1.1 equiv) in anhydrous DMF (0.3 M) was added HATU (1.3 equiv) at 0°C. After stirring for 10 minutes, amine (1.0 equiv) and DIEA (3.0 equiv) were slowly added. The resulting reaction mixture was warmed to r.t. and stirred for several hours until the reaction is complete as indicated by TLC. The reaction mixture was diluted with EtOAc and water, the separated organic layer was washed sequentially with 5% citric acid solution, half-saturated aqueous NaCl for five times, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product, which was purified by column chromatography on silica gel (PE/EA 100:1).

General Procedure B: Preparation of 2,3-dihydropyrroles (4)

A solution of amine (1.0 equiv), aldehyde (2.0 equiv), pyruvic amide (2.0 equiv) and acetic acid (V_{EtOH} : V_{AcOH} = 12:1) in anhydrous EtOH (amine concentration: 0.025 mol/L) was stirred under reflux for 8 h. After cooled down to r.t., ethanol was removed under vacuum,

and the residue was diluted with EtOAc and water. After separation, the aqueous phase was extracted two more times with EtOAc. The combined organic phases were successively washed with saturated aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, concentrated *in vacuo* and chromatographed gradiently on silica gel with PE/EA (5:1~3:1) to give the dihydropyrrole products.


2. Preparation Procedure for 3, 4, 5 and 6



***N*-(4-Chlorophenyl)-2-oxopropanamide (3a)**

3a


Using 4-chloroaniline (1.0 g, 7.8 mmol), in accordance with General Procedure A, the title compound **3a** was obtained (810 mg, 52% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.73 (s, 1H), 7.60 (d, *J* = 8.0 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 2.57 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 197.1, 157.6, 135.0, 130.6, 129.5, 121.1, 24.2. HRMS (ESI-TOF) *m/z* calcd. for C₉H₇NO₂Cl⁺ [M-H]⁺: 196.0171, found 196.0170.



***N*-(3-Chlorophenyl)-2-oxopropanamide (3b)**

3b

Using 3-chloroaniline (1.0 g, 7.8 mmol), in accordance with General Procedure A, the title compound **3b** was obtained (900 mg, 59% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.73 (s, 1H), 7.78 (t, *J* = 2.0 Hz, 1H), 7.46 (dd, *J* = 1.6, 8.0 Hz, 1H), 7.29 (t, *J* = 8.0 Hz, 1H), 7.16 (d, *J* = 8.0 Hz, 1H), 2.57 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 197.0, 157.7, 137.5, 135.1, 130.4, 125.5, 120.0, 117.9, 24.1. HRMS (ESI-TOF) *m/z* calcd. for C₉H₇NO₂Cl⁺ [M-H]⁺: 196.0171, found 196.0172.




3c

***N*-(2-Chlorophenyl)-2-oxopropanamide (3c)**


To a solution of pyruvic acid (2.8 g, 31.4 mmol) in anhydrous DMF (30 ml) was added HBTU (11.9 g, 31.4 mmol) at 0 °C. After stirring for 10 minutes, 2-chloroaniline (2.0 g, 15.7 mmol) and DIEA (6.1 g, 47.1 mmol) were slowly added. The resulting reaction mixture was warmed to r.t. and stirred for several hours until the reaction is complete as indicated by TLC. The reaction mixture was diluted with EtOAc and water, the separated organic layer was washed sequentially with 5% citric acid solution, half-saturated aqueous NaCl for five times, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product, which was purified by column chromatography on silica gel (PE/EA 100:1) to produce the imine intermediate (~ 600 mg).

A solution of the intermediate (500 mg) in THF (12 ml) and 2 M HCl (5 ml) was stirred under reflux for 3 h. The reaction mixture was diluted with EtOAc and water, the separated organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford **3c** (316 mg, 98% yield) as a pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 9.38 (s, 1H), 8.45 (d, *J* = 8.4 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.32 (t, *J* = 8.0 Hz, 1H), 7.11 (t, *J* = 8.0 Hz, 1H), 2.58 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 196.7, 157.7, 133.3, 129.5, 128.0, 125.8, 123.9, 121.1, 24.1. HRMS (ESI-TOF) *m/z* calcd. for C₉H₇NO₂Cl⁻ [M-H]⁻: 196.0171, found 196.0166.



2-Oxo-*N*-phenylpropanamide (3d)


Using aniline (3.0 g, 7.8 mmol), in accordance with General Procedure A, the title compound **3d** was obtained (3.0 g, 57% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.72 (s, 1H), 7.64 (d, *J* = 7.6 Hz, 2H), 7.38 (t, *J* = 8.0 Hz, 2H), 7.18 (t, *J* = 7.6 Hz, 1H), 2.57 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 197.5, 157.7, 136.4, 129.4, 125.4, 119.8, 24.2. HRMS (ESI-TOF) *m/z* calcd. for C₉H₁₀NO₂ [M+H]⁺: 164.0706, found 164.0712.



***N*-(4-Methoxyphenyl)-2-oxopropanamide (3e)**

To a solution of pyruvic acid (1.2 g, 13.6 mmol) in anhydrous DMF (20 ml) was added HATU (6.7 g, 17.7 mmol) at 0 °C. After stirring for 10 minutes, *p*-anisidine (3.0 g, 24.4 mmol) and DIEA (5.3 g, 41.0 mmol) were slowly added. The resulting reaction mixture was warmed to r.t. and stirred for several hours until the reaction is complete as indicated by TLC. The reaction mixture was diluted with EtOAc and water, the separated organic layer was washed sequentially with 5% citric acid solution, and half-saturated aqueous NaCl for five times, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product, which was purified by column chromatography on silica gel (PE/EA 100:1~50:1) to produce the imine intermediate (~1.6 g).


A solution of the imine intermediate (1.2 g, 4.0 mmol) in THF (45 ml) and 1 M HCl (24 ml) was stirred under reflux for 3 h. The reaction mixture was diluted with EtOAc and water, the separated organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product, which was purified by column chromatography on silica gel (PE/EA 10:1) to afford **3e** (720 mg, 93% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.65 (s, 1H), 7.56 (d, *J* = 8.8 Hz, 2H), 6.90 (d, *J* = 8.8 Hz, 2H), 3.81 (s, 3H), 2.56 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 157.4, 157.2, 129.6, 121.4, 114.5, 55.6, 24.3. HRMS (ESI-TOF) *m/z* calcd. for C₁₀H₁₀NO₃⁻ [M-H]⁻: 192.0666, found 192.0665.



***N*-(4-Fluorophenyl)-2-oxopropanamide (3f)**

3f

Using *p*-fluoroaniline (1.0 g, 9.0 mmol), in accordance with General Procedure A, the title compound **3f** was obtained (350 mg, 22% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.71 (s, 1H), 7.61 (dd, *J* = 4.8, 8.8 Hz, 2H), 7.06 (t, *J* = 8.8 Hz, 2H), 2.56 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 197.3, 161.2, 158.2 (d, *J* = 119.0 Hz), 132.5 (d, *J* = 2.0 Hz), 121.6 (d, *J* = 8.0 Hz), 116.1 (d, *J* = 23.0 Hz), 24.2. HRMS (ESI-TOF) *m/z* calcd. for C₉H₇NO₂F⁺ [M-H]⁺: 180.0466, found 180.0461.




2-Oxo-*N*-(*p*-tolyl)propanamide (**3g**)

A solution of pyruvic acid (5.0 g, 57 mmol) in SOCl₂ (30 ml) was refluxed for 2 h. After cooled down to r.t., SOCl₂ was removed under vacuum to afford the acyl chloride intermediate.

To a cold (0 °C) solution of acyl chloride in dichloromethane (15 ml) was added *p*-toluidine (15.3 g, 143 mmol) and Et₃N (23 g, 228 mmol). The medium was stirred at room temperature for several hours until the reaction is complete as indicated by TLC. The reaction mixture was diluted with dichloromethane and water, the separated organic layer was washed with 1 M HCl, brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product, which was purified by column chromatography on silica gel (PE/EA 50:1) to give the imine intermediate (~4.0 g).


A solution of the imine intermediate (4.0 g) in THF (20 ml) and 3 M HCl (20 ml) was stirred under reflux for 3 h. The reaction mixture was diluted with EtOAc and water, the separated organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated under vacuum to afford the crude product, which was purified by column chromatography on silica gel (PE/EA 10:1) to afford **3g** (2.2 g, 82% yield) as a pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.67 (s, 1H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.17 (d, *J* = 8.4 Hz, 2H), 2.56 (s, 3H), 2.34 (s,

3H). ^{13}C NMR (100 MHz, CDCl_3) δ 197.6, 157.6, 135.2, 133.9, 129.9, 119.8, 24.2, 21.1. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{10}\text{H}_{10}\text{NO}_2^- [\text{M}-\text{H}]^-$: 176.0717, found 176.0724.




***N*-Butyl-2-oxopropanamide (3h)**

Using *n*-butylamine (1.0 g, 13.7 mmol), in accordance with General Procedure A, the title compound **3h** was obtained (504 mg, 26% yield) as a purple solid. ^1H NMR (400 MHz, CDCl_3) δ 6.96 (s, 1H), 3.29-3.24 (m, 2H), 2.45 (s, 3H), 1.54-1.47 (m, 2H), 1.34 (sxt, $J = 7.2$ Hz, 2H), 0.91 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 197.3, 160.2, 39.0, 31.2, 24.4, 19.9, 13.6. HRMS (ESI-TOF) m/z calcd. for $\text{C}_7\text{H}_{14}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 144.1019, found 144.1018.



***N*-Cyclohexyl-2-oxopropanamide (3i)**


Using cyclohexylamine (1.0 g, 10.1 mmol), in accordance with General Procedure A, the title compound **3i** was obtained (1.0 g, 61% yield) as a brown crystal. ^1H NMR (400 MHz, CDCl_3) δ 6.81 (s, 1H), 3.76-3.67 (m, 1H), 2.46 (s, 3H), 1.92-1.88 (m, 2H), 1.75-1.64 (m, 2H), 1.63-1.60 (m, 2H), 1.42-1.32 (m, 2H), 1.25-1.16 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 197.8, 159.3, 48.5, 32.8, 25.5, 24.8, 24.5. HRMS (ESI-TOF) m/z calcd. for $\text{C}_9\text{H}_{16}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 170.1176, found 170.1179.



***N*-(3-Chlorophenyl)-2-oxobutanamide (3j)**


Using 3-chloroaniline (1.5 g, 11.8 mmol) and 2-oxobutyric acid (1.3 g, 13 mmol) in accordance with General Procedure A, the title compound **3j** was obtained (270 mg, 11% yield) as a pale yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.75 (s, 1H), 7.79 (t, $J = 2.0$ Hz, 1H), 7.47 (dd, $J = 1.2, 8.0$ Hz, 1H), 7.29 (t, $J = 8.0$ Hz, 1H), 7.15 (dd, $J = 1.2, 8.0$ Hz, 1H),

3.05 (q, $J = 7.2$ Hz, 2H), 1.17 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 199.6, 157.7, 137.6, 135.1, 130.4, 125.5, 120.0, 117.9, 30.1, 7.3. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{10}\text{H}_9\text{NO}_2\text{Cl}^-$ [M-H] $^-$: 210.0327, found 210.0326.



***N*-(4-chlorophenyl)-2-oxobutanamide (3k)**

Using 4-chloroaniline (2.6 g, 20.2 mmol) and 2-oxobutyric acid (3.3 g, 32.3 mmol) in accordance with General Procedure A, the title compound **3k** was obtained (900 mg, 20% yield) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.76 (s, 1H), 7.60 (d, $J = 8.8$ Hz, 2H), 7.33 (d, $J = 8.8$ Hz, 2H), 3.04 (q, $J = 7.2$ Hz, 2H), 1.61 (t, $J = 7.2$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 199.8, 157.6, 135.1, 130.5, 129.4, 121.1, 30.1, 7.3. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{10}\text{H}_9\text{NO}_2\text{Cl}^-$ [M-H] $^-$: 210.0327, found 210.0327.




***N*-(3-chlorophenyl)-2-oxo-2-phenylacetamide (3l)**

A solution of benzoylformic acid (3.0 g, 20 mmol) in SOCl_2 (20 ml) was refluxed for 2 h. After cooled down to r.t., SOCl_2 was removed under vacuum to afford the acyl chloride intermediate.

To a cold (0 °C) solution of acyl chloride in dichloromethane (10 ml) was added 3-chloroaniline (2.8 g, 22 mmol) and Et_3N (8.0 g, 80 mmol). The medium was stirred at room temperature for several hours until the reaction is complete as indicated by TLC. The reaction mixture was diluted with dichloromethane and water, the separated organic layer was washed with 1 M HCl, brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure to afford the crude product, which was purified by column chromatography on silica gel (PE/EA 50:1) to give the imine intermediate (~2.7 g).


A solution of the imine intermediate (2.4 g) in THF (30 ml) and 2 M HCl (20 ml) was stirred under reflux for 3 h. The reaction mixture was diluted with EtOAc and water, the separated

organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated under vacuum to afford the crude product, which was purified by column chromatography on silica gel (PE/EA 10:1) to afford **3l** (1.5 g, 88% yield) as a pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.97 (s, 1H), 8.42 (d, *J* = 7.6 Hz, 2H), 7.872-7.868 (m, 1H), 7.68 (t, *J* = 7.6 Hz, 1H), 7.53 (t, *J* = 8.0 Hz, 3H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.18 (d, *J* = 8.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 187.0, 158.9, 137.9, 135.1, 135.0, 133.0, 131.7, 130.4, 128.8, 125.5, 120.2, 118.0. HRMS (ESI-TOF) *m/z* calcd. for C₁₄H₉NO₂Cl⁺ [M-H]⁺: 258.0327, found 258.0339.




(2S,3R)-N-(4-Chlorophenyl)-4-(2-((4-chlorophenyl)amino)-2-oxoacetyl)-1-(4-methoxyphenyl)-2-methyl-3,5-di-*p*-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4a)

Using *p*-anisidine (31 mg, 0.25 mmol), *p*-tolualdehyde (60 mg, 0.5 mmol), and **3a** (100 mg, 0.5 mmol) in accordance with General Procedure B, the title compound was obtained (89 mg, 51% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 8.03 (s, 1H), 7.20-7.15 (m, 6H), 7.10 (d, *J* = 8.4 Hz, 4H), 7.03 (d, *J* = 8.4 Hz, 2H), 6.97 (d, *J* = 8.0 Hz, 4H), 6.86 (d, *J* = 9.2 Hz, 2H), 6.68 (d, *J* = 8.8 Hz, 2H), 5.11 (s, 1H), 3.70 (s, 3H), 2.22 (s, 3H), 2.19 (s, 3H), 1.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 184.4, 168.3, 166.3, 162.4, 158.3, 140.5, 137.3, 135.8, 135.6, 134.2, 130.8, 129.6, 129.33, 129.26, 129.21, 129.1, 128.84, 128.77, 128.69, 128.3, 128.0, 121.6, 121.1, 114.4, 111.0, 78.6, 61.0, 55.4, 23.5, 21.5, 21.1. HRMS (ESI-TOF) *m/z* calcd. for C₄₁H₃₆N₃O₄Cl₂ [M+H]⁺: 704.2077, found 704.2052.



(2S,3R)-N-(3-Chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-1-(4-methoxyphenyl)-2-methyl-3,5-di-*p*-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4b)


Using *p*-anisidine (31 mg, 0.25 mmol), *p*-tolualdehyde (60 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was obtained (87 mg, 49% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.63 (s, 1H), 7.79 (s, 1H), 7.22-7.20 (m, 3H), 7.18-7.13 (m, 4H), 7.11-7.09 (m, 1H), 7.05-6.95 (m, 8H), 6.88 (d, *J* = 8.8 Hz, 2H), 6.68 (d, *J* = 8.8 Hz, 2H), 5.16 (s, 1H), 3.71 (s, 3H), 2.28 (s, 3H), 2.20 (s, 3H), 1.70 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 184.2, 168.4, 166.5, 162.6, 162.5, 158.3, 140.6, 138.3, 138.1, 137.5, 134.4, 134.3, 130.9, 129.73, 129.67, 129.4, 129.3, 129.1, 128.9, 128.3, 128.0, 124.8, 124.3, 120.8, 120.1, 118.7, 118.0, 114.4, 111.0, 78.7, 60.8, 55.4, 23.7, 21.4, 21.1. HRMS (ESI-TOF) *m/z* calcd. for C₄₁H₃₆N₃O₄Cl₂ [M+H]⁺: 704.2077, found 704.2076.



(2S,3R)-N-(2-Chlorophenyl)-4-(2-((2-chlorophenyl)amino)-2-oxoacetyl)-1-(4-methoxyphenyl)-2-methyl-3,5-di-*p*-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4c)

Using *p*-anisidine (31 mg, 0.25 mmol), *p*-tolualdehyde (60 mg, 0.5 mmol), and **3c** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was obtained (109 mg, 62% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.93 (s, 1H), 8.79 (s, 1H), 7.70 (dd, *J* = 8.0, 14.0 Hz, 2H), 7.37-7.35 (m, 1H), 7.32-7.29 (m, 2H), 7.271-7.269 (m, 1H), 7.18 (d, *J* = 8.0 Hz, 2H), 7.14-7.06 (m, 4H), 7.02-6.97 (m, 1H), 6.94 (d, *J* = 8.8 Hz, 3H), 6.90 (d, *J* = 7.6 Hz, 2H), 6.66 (d, *J* = 8.8 Hz, 2H), 5.28 (s, 1H), 3.70 (s, 3H), 2.28 (s, 3H), 2.10 (s, 3H), 1.65 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 183.8, 168.6, 166.0, 161.5, 158.3, 140.2, 137.1, 135.2, 134.1, 133.9, 131.5, 129.40, 129.35, 129.23, 129.18, 129.10, 128.9, 128.5, 128.3, 127.6, 127.4, 124.83, 124.76, 123.5, 122.9, 121.23, 121.20, 114.4, 111.8, 78.9, 61.5,


55.4, 24.3, 21.6, 21.0. HRMS (ESI-TOF) m/z calcd. for $C_{41}H_{36}N_3O_4Cl_2$ $[M+H]^+$: 704.2077, found 704.2079.



4d

(2S,3R)-1-(4-Methoxyphenyl)-2-methyl-4-(2-oxo-2-(phenylamino)acetyl)-N-phenyl-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4d)

Using *p*-anisidine (74 mg, 0.6 mmol), *p*-tolualdehyde (144 mg, 1.2 mmol), and **3d** (200 mg, 1.2 mmol), in accordance with General Procedure B, the title compound was obtained (75 mg, 20% yield) as a yellow solid. 1H NMR (400 MHz, CD_3OD) δ 7.32-7.28 (m, 4H), 7.21-7.14 (m, 4H), 7.12-7.07 (m, 3H), 7.05-6.99 (m, 5H), 6.93 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H), 6.70 (d, J = 8.4 Hz, 2H), 4.83 (s, 1H), 3.64 (s, 3H), 2.22 (s, 3H), 2.04 (s, 3H), 1.75 (s, 3H). ^{13}C NMR (100 MHz, CD_3OD) δ 185.8, 170.6, 169.5, 167.4, 160.2, 141.4, 138.8, 138.1, 137.9, 135.9, 132.0, 131.5, 131.1, 130.1, 129.7, 129.6, 129.29, 129.26, 128.7, 126.3, 125.4, 124.1, 121.5, 115.1, 111.7, 79.7, 60.9, 55.8, 25.0, 21.3, 21.1. HRMS (ESI-TOF) m/z calcd. for $C_{41}H_{38}N_3O_4$ $[M+H]^+$: 636.2857, found 636.2840.




4e

(2S,3R)-1-Butyl-N-(3-chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-2-methyl-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4e)


Using *p*-anisidine (62 mg, 0.5 mmol), *p*-tolualdehyde (120 mg, 1.0 mmol), and **3e** (200 mg, 1.0 mmol), in accordance with General Procedure B, the title compound was obtained (105 mg, 30% yield) as a yellow crystalline solid. 1H NMR (400 MHz, CD_3OD) δ 7.32-7.26 (m,

4H), 7.05 (d, $J = 10.0$ Hz, 3H), 7.01 (d, $J = 4.0$ Hz, 2H), 6.99 (s, 1H), 6.89 (d, $J = 8.0$ Hz, 2H), 6.74 (s, 4H), 6.72-6.70 (m, 4H), 4.83 (s, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 3.66 (s, 3H), 2.26 (s, 3H), 2.09 (s, 3H), 1.73 (s, 3H). ^{13}C NMR (100 MHz, CD_3OD) δ 185.9, 170.7, 169.4, 167.1, 160.2, 158.8, 158.0, 141.3, 137.9, 136.03, 136.01, 132.1, 131.8, 131.5, 131.1, 130.9, 130.2, 129.7, 129.6, 128.8, 126.0, 123.1, 115.1, 114.5, 111.8, 79.5, 61.0, 55.82, 55.81, 55.80, 25.1, 21.3, 21.2. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{43}\text{H}_{42}\text{N}_3\text{O}_6$ $[\text{M}+\text{H}]^+$: 696.3068, found 696.3066.




(2S,3R)-N-(4-Fluorophenyl)-4-(2-((4-fluorophenyl)amino)-2-oxoacetyl)-1-(4-methoxyphenyl)-2-methyl-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4f)

Using *p*-anisidine (62 mg, 0.5 mmol), *p*-tolualdehyde (120 mg, 1.0 mmol), and **3f** (180mg, 1.0 mmol), in accordance with General Procedure B, the title compound was obtained (85 mg, 25% yield) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, $J = 12.0$ Hz, 1H), 7.89 (d, $J = 7.6$ Hz, 1H), 7.22 (d, $J = 8.0$ Hz, 2H), 7.16 (d, $J = 8.0$ Hz, 2H), 7.11-7.03 (m, 6H), 6.98 (d, $J = 7.6$ Hz, 2H), 6.93-6.87 (m, 6H), 6.68 (d, $J = 8.8$ Hz, 2H), 5.20 (s, 1H), 3.71 (s, 3H), 2.29 (s, 3H), 2.19 (s, 3H), 1.69 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 183.9, 168.3, 166.1, 161.6, 161.0, 160.7, 158.5, 158.4, 158.3, 140.4, 137.4, 134.9, 133.10, 133.06, 131.2, 129.4, 129.2, 128.9, 128.5, 128.4, 122.3 (d, $J = 7.0$ Hz), 121.6 (d, $J = 8.0$ Hz), 115.7 (d, $J = 4.0$ Hz), 115.5 (d, $J = 4.0$ Hz), 114.5, 78.7, 61.3, 55.5, 23.8, 21.6, 21.2. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{41}\text{H}_{36}\text{N}_3\text{O}_4\text{F}_2$ $[\text{M}+\text{H}]^+$: 672.2668, found 672.2681.



(2S,3R)-1-(4-Methoxyphenyl)-2-methyl-4-(2-oxo-2-(p-tolylamino)acetyl)-N,3,5-tri-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4g)


Using *p*-anisidine (172 mg, 1.4 mmol), *p*-tolualdehyde (336 mg, 2.8 mmol), and **3g** (500 mg, 2.8 mmol), in accordance with General Procedure B, the title compound was obtained (238 mg, 23% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 7.91 (s, 1H), 7.22 (d, *J* = 7.6 Hz, 2H), 7.18 (d, *J* = 7.6 Hz, 2H), 7.07-6.97 (m, 12H), 6.88 (d, *J* = 8.8 Hz, 2H), 6.66 (d, *J* = 8.8 Hz, 2H), 5.21 (s, 1H), 3.70 (s, 3H), 2.28 (s, 6H), 2.26 (s, 3H), 2.19 (s, 3H), 1.68 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 184.8, 168.0, 165.8, 162.2, 162.1, 158.0, 140.0, 136.8, 134.54, 134.50, 134.3, 134.0, 133.6, 131.0, 129.2, 129.1, 129.0, 128.9, 128.8, 128.3, 128.1, 120.5, 119.8, 114.1, 111.2, 78.3, 60.8, 55.2, 23.5, 21.3, 21.0, 20.80, 20.79. HRMS (ESI-TOF) *m/z* calcd. for C₄₃H₄₂N₃O₄ [M+H]⁺: 664.3170, found 664.3168.



(2S,3R)-1-(4-(Benzyloxy)phenyl)-N-(3-chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-2-methyl-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4j)


Using BnOPhNH₂ (50 mg, 0.25 mmol), *p*-tolualdehyde (60 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol) in accordance with General Procedure B, the title compound was obtained (73 mg, 37% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.36-7.35 (m, 4H), 7.21(d, *J* = 8.4 Hz, 3H), 7.17-7.11 (m, 5H), 7.07 (d, *J* = 8.4 Hz, 3H), 7.03-6.94 (m, 6H), 6.88 (d, *J* = 8.8

Hz, 2H), 6.75 (d, J = 8.8 Hz, 2H), 5.19 (s, 1H), 4.94 (s, 2H), 2.31 (s, 3H), 2.20 (s, 3H), 1.71 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 184.0, 168.3, 166.4, 162.1, 162.0, 157.5, 140.6, 138.2, 138.0, 137.6, 136.4, 134.6, 134.5, 134.4, 131.2, 129.79, 129.76, 129.42, 129.35, 129.2, 128.9, 128.7, 128.24, 128.15, 127.6, 124.8, 124.4, 120.5, 120.0, 118.4, 117.9, 115.4, 111.1, 78.8, 70.3, 60.9, 23.6, 21.5, 21.0. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{47}\text{H}_{40}\text{Cl}_2\text{N}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 780.2390, found 780.2401.




(2S,3R)-1-([1,1'-Biphenyl]-4-yl)-N-(3-chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-2-methyl-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4k)

Using 4-aminobiphenyl (42 mg, 0.25 mmol), *p*-tolualdehyde (60 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was obtained (49 mg, 26% yield) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.60 (s, 1H), 7.84 (s, 1H), 7.48 (d, J = 7.2 Hz, 2H), 7.41-7.38 (m, 4H), 7.34-7.30 (m, 1H), 7.27 (s, 1H), 7.25 (s, 1H), 7.22 (s, 1H), 7.18-7.13 (m, 5H), 7.11-7.07 (m, 3H), 7.03-6.97 (m, 7H), 5.21 (s, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 1.77 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 184.3, 168.4, 165.4, 161.7, 140.9, 139.6, 139.5, 138.2, 138.1, 137.7, 137.6, 134.51, 134.49, 134.3, 129.9, 129.8, 129.5, 129.4, 129.0, 128.27, 128.25, 128.1, 127.81, 127.77, 127.3, 126.9, 124.9, 124.6, 120.7, 120.1, 118.6, 118.0, 111.9, 78.8, 61.3, 23.6, 21.6, 21.2. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{46}\text{H}_{38}\text{Cl}_2\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$: 750.2285, found 750.2258.



(2S,3R)-1-Butyl-N-(3-chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-2-methyl-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4n)


Using butylamine (19 mg, 0.25 mmol), *p*-tolualdehyde (60 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, except that no acetic acid was added in the reaction media, the title compound was obtained (87 mg, 51% yield) as a yellow crystalline solid. ¹H NMR (400 MHz, CDCl₃) δ 8.72 (s, 1H), 7.46-7.38 (m, 2H), 7.29 (s, 2H), 7.15 (d, *J* = 7.6 Hz, 2H), 7.12-7.07 (m, 3H), 7.04-6.97 (m, 5H), 6.90 (s, 1H), 6.83 (d, *J* = 8.0 Hz, 1H), 5.04 (s, 1H), 3.25-3.18 (m, 1H), 3.12-3.05 (m, 1H), 2.43 (s, 3H), 2.18 (s, 3H), 1.88 (s, 3H), 1.33-1.30 (m, 2H), 1.01 (sxt, *J* = 7.2 Hz, 2H), 0.66 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 180.6, 169.2, 168.5, 162.0, 140.2, 138.4, 137.84, 137.83, 137.5, 136.4, 134.5, 134.4, 129.8, 129.7, 129.6, 128.7, 127.9, 124.9, 124.3, 120.8, 120.7, 119.8, 118.6, 117.7, 110.1, 79.1, 58.4, 45.5, 32.4, 23.3, 21.7, 21.0, 20.3, 13.4. HRMS (ESI-TOF) *m/z* calcd. for C₃₈H₃₇N₃O₃Cl₂Na⁺ [M+Na]⁺: 676.2104, found 676.2092.



(2S,3R)-1-Benzyl-N-(3-chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-2-methyl-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4o)


Using benzylamine (54 mg, 0.5 mmol), *p*-tolualdehyde (120 mg, 1.0 mmol), and **3b** (200 mg, 1.0 mmol), in accordance with General Procedure B, the title compound was obtained (94 mg, 28% yield) as a yellow solid. The single crystal was obtain by wap crystallization. ¹H NMR

(400 MHz, CDCl₃) δ 8.63 (s, 1H), 7.29 (s, 1H), 7.24-7.18 (m, 7H), 7.11-7.05 (m, 4H), 7.03-6.95 (m, 6H), 6.66-6.59 (m, 3H), 5.10 (s, 1H), 4.57 (d, J = 16.4 Hz, 1H), 4.34 (d, J = 16.0 Hz, 1H), 2.37 (s, 3H), 2.17 (s, 3H), 1.79 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 181.0, 169.7, 168.0, 161.8, 140.1, 138.3, 137.7, 137.6, 137.4, 136.4, 134.5, 134.1, 129.8, 129.65, 129.64, 129.62, 129.5, 128.9, 128.6, 128.0, 127.8, 127.3, 124.7, 124.4, 120.5, 119.8, 118.4, 117.7, 110.5, 79.6, 58.8, 48.7, 23.5, 21.6, 21.0. HRMS (ESI-TOF) m/z calcd. for C₄₁H₃₆N₃O₃Cl₂ [M+H]⁺: 688.2128, found 688.2119.




(2S,3R)-N-(3-Chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-3,5-bis(2-methoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4p)

Using *p*-anisidine (31 mg, 0.25 mmol), 2-methoxy-benzaldehyde (68 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was obtained (63 mg, 34% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 9.20 (s, 1H), 8.38 (s, 1H), 7.46 (s, 1H), 7.35-7.34 (m, 2H), 7.21-7.17 (m, 3H), 7.13-7.06 (m, 4H), 6.99 (d, J = 8.0 Hz, 1H), 6.94-6.92 (m, 2H), 6.87-6.83 (m, 4H), 6.64 (d, J = 8.8 Hz, 2H), 6.53-6.49 (m, 1H), 5.79 (s, 1H), 3.92 (s, 3H), 3.69 (s, 3H), 3.65 (s, 3H), 1.70 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 183.4, 168.9, 163.1, 161.4, 158.4, 158.2, 156.1, 139.0, 138.2, 134.7, 134.6, 131.8, 130.7, 130.0, 129.8, 128.6, 127.9, 127.8, 124.5, 124.4, 121.3, 121.1, 120.4, 120.2, 120.06, 120.05, 118.2, 117.9, 113.99, 113.97, 112.7, 111.9, 111.0, 78.8, 56.3, 55.7, 55.4, 53.8, 22.7. HRMS (ESI-TOF) m/z calcd. for C₄₁H₃₆Cl₂N₃O₆ [M+H]⁺: 736.1976, found 736.1986.



(2S,3R)-N-(3-Chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-3,5-bis(3-methoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4q)


Using *p*-anisidine (31 mg, 0.25 mmol), 3-methoxy-benzaldehyde (68 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was obtained (69 mg, 38% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (s, 1H), 7.65 (s, 1H), 7.27 (s, 1H), 7.22-7.20 (m, 2H), 7.18-7.10 (m, 3H), 7.03 (t, *J* = 8.8 Hz, 3H), 6.96 (d, *J* = 8.4 Hz, 1H), 6.91-6.83 (m, 7H), 6.69-6.65 (m, 3H), 5.19 (s, 1H), 3.71 (s, 3H), 3.64 (s, 3H), 3.59 (s, 3H), 1.73 (s, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 185.2, 170.6, 169.0, 167.3, 161.0, 160.42, 160.36, 140.4, 140.2, 139.6, 134.9, 134.8, 132.7, 131.79, 131.78, 131.51, 131.49, 130.7, 130.6, 130.13, 130.10, 130.05, 130.04, 126.0, 125.1, 123.8, 121.9, 121.3, 119.5, 115.12, 115.11, 113.7, 111.6, 79.8, 61.3, 55.8, 55.6, 55.5, 24.7. HRMS (ESI-TOF) *m/z* calcd. for C₄₁H₃₆Cl₂N₃O₆ [M+H]⁺: 736.1976, found 736.1974.



(2S,3R)-N-(3-Chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-1,3,5-tris(4-methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4r)


Using *p*-anisidine (31 mg, 0.25 mmol), 4-methoxy-benzaldehyde (68 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was

obtained (73 mg, 40% yield) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.81 (s, 1H), 8.14 (s, 1H), 7.25-7.23 (m, 4H), 7.21-7.17 (m, 2H), 7.15-7.11 (m, 1H), 7.09-7.05 (m, 2H), 7.03-6.96 (m, 4H), 6.86 (d, J = 8.8 Hz, 2H), 6.70-6.67 (m, 5H), 5.06 (s, 1H), 3.71 (s, 3H), 3.68 (s, 3H), 3.65 (s, 3H), 1.65 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 184.1, 168.6, 166.2, 162.54, 162.50, 161.2, 159.2, 158.4, 138.4, 138.25, 138.23, 134.5, 131.24, 131.23, 131.1, 129.8, 129.5, 129.0, 124.8, 124.5, 123.2, 120.8, 120.1, 118.7, 118.0, 114.6, 114.1, 113.9, 110.9, 78.6, 60.7, 55.5, 55.34, 55.27, 23.9. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{41}\text{H}_{36}\text{Cl}_2\text{N}_3\text{O}_6$ $[\text{M}+\text{H}]^+$: 736.1976, found 736.1956.




(2S,3R)-N,3,5-Tris(3-chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-1-(4-methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4s)

Using *p*-anisidine (31 mg, 0.25 mmol), 3-chlorobenzaldehyde (70 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was obtained (56 mg, 30% yield) as a yellow crystalline solid. ^1H NMR (400 MHz, CD_3OD) δ 7.47 (d, J = 10.4 Hz, 2H), 7.36-7.32 (m, 2H), 7.29 (s, 1H), 7.22-7.18 (m, 2H), 7.17-7.13 (m, 2H), 7.11-7.06 (m, 7H), 7.04-6.98 (m, 2H), 6.74 (d, J = 8.8 Hz, 2H), 4.86 (s, 1H), 3.66 (s, 3H), 1.80 (s, 3H). ^{13}C NMR (100 MHz, CD_3OD) δ 184.8, 170.0, 167.7, 167.1, 160.6, 141.4, 140.0, 139.4, 135.1, 135.0, 134.90, 134.89, 133.4, 131.9, 131.1, 131.0, 130.8, 130.7, 130.6, 130.51, 130.45, 129.4, 128.5, 126.1, 125.3, 123.6, 121.7, 121.12, 121.11, 119.3, 115.22, 115.21, 111.3, 80.0, 60.7, 55.8, 24.4. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{39}\text{H}_{30}\text{Cl}_4\text{N}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 744.0985, found 744.0984.



(2S,3R)-N-(3-Chlorophenyl)-3,5-bis(4-chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-1-(4-methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4t)


Using *p*-anisidine (31 mg, 0.25 mmol), 4-chlorobenzaldehyde (70 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was obtained (55 mg, 30% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.66 (s, 1H), 7.57 (s, 1H), 7.28-7.21 (m, 7H), 7.17-7.13 (m, 5H), 7.09-6.99 (m, 3H), 6.88 (d, *J* = 8.4 Hz, 3H), 6.70 (d, *J* = 8.4 Hz, 2H), 5.23 (s, 1H), 3.72 (s, 3H), 1.72 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 182.7, 167.8, 165.7, 161.3, 158.8, 137.9, 137.6, 136.7, 136.4, 134.7, 133.8, 130.6, 130.2, 130.06, 130.05, 129.7, 129.6, 129.29, 129.28, 128.90, 128.88, 125.3, 124.9, 120.6, 119.9, 118.4, 117.8, 114.7, 110.8, 79.0, 60.7, 55.5, 23.9. HRMS (ESI-TOF) *m/z* calcd. for C₃₉H₃₀Cl₄N₃O₄ [M+H]⁺: 744.0985, found 744.0968.



(2S,3R)-1-(4-(Benzyloxy)phenyl)-N-(3-chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-3,5-bis(4-methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4u)


Using BnOPhNH₂ (76 mg, 0.38 mmol), 4-methoxy-benzaldehyde (103 mg, 0.76 mmol), and **3b** (150 mg, 0.76 mmol), in accordance with General Procedure B, the title compound was obtained (100 mg, 32% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.65 (s, 1H),

7.86 (s, 1H), 7.36-7.35 (m, 6H), 7.25-7.23 (m, 3H), 7.18 (d, $J = 8.4$ Hz, 2H), 7.15-7.09 (m, 2H), 7.05-6.97 (m, 4H), 6.86 (d, $J = 8.4$ Hz, 2H), 6.77-6.69 (m, 6H), 5.11 (s, 1H), 4.95 (s, 2H), 3.71 (s, 3H), 3.65 (s, 3H), 1.68 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 184.1, 168.5, 166.1, 162.4, 161.2, 159.2, 157.6, 138.4, 138.2, 136.4, 134.52, 134.45, 131.3, 131.19, 131.17, 129.88, 129.84, 129.5, 128.8, 128.7, 128.3, 127.6, 124.8, 124.5, 123.1, 120.6, 120.0, 118.5, 118.0, 115.5, 114.1, 114.0, 110.9, 78.6, 70.3, 60.7, 55.4, 55.3, 23.7. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{47}\text{H}_{39}\text{Cl}_2\text{N}_3\text{O}_6\text{Na}^+ [\text{M}+\text{Na}]^+$: 834.2108, found 834.2102.




(2S,3R)-N-(3-Chlorophenyl)-4-(2-((3-chlorophenyl)amino)-2-oxoacetyl)-3,5-di(furan-2-yl)-1-(4-methoxyphenyl)-2-methyl-2,3-dihydro-1H-pyrrole-2-carboxamide (4v)

Using *p*-anisidine (31 mg, 0.25 mmol), furan-2-carbaldehyde (48 mg, 0.5 mmol), and **3b** (100 mg, 0.5 mmol), in accordance with General Procedure B, the title compound was obtained (31 mg, 19% yield) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.72 (s, 1H), 8.49 (s, 1H), 7.57-7.55 (m, 2H), 7.32 (s, 1H), 7.28-7.26 (m, 2H), 7.23-7.18 (m, 3H), 7.09-7.06 (m, 2H), 6.99 (d, $J = 8.8$ Hz, 2H), 6.81 (d, $J = 8.8$ Hz, 2H), 6.38-6.37 (m, 1H), 6.28-6.27 (m, 1H), 6.21 (s, 2H), 5.16 (s, 1H), 3.78 (s, 3H), 1.62 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 184.0, 168.3, 161.6, 159.2, 153.2, 150.5, 144.9, 144.2, 142.6, 138.7, 138.5, 134.8, 134.6, 131.1, 130.1, 130.0, 128.7, 124.73, 124.69, 120.5, 119.8, 118.5, 117.8, 116.6, 114.8, 112.4, 110.8, 109.0, 107.2, 76.9, 55.6, 55.0, 22.9. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{35}\text{H}_{28}\text{Cl}_2\text{N}_3\text{O}_6$ $[\text{M}+\text{H}]^+$: 656.1350, found 656.1348.




(E)-1-(4-Nitrophenyl)-3-(p-tolyl)prop-2-en-1-one (5a)

4-Tolualdehyde (0.73 g, 6.05 mmol) and a 6 M NaOH aqueous solution (50 μ L, 0.3 mmol) were successively added to a solution of 4-nitroacetophenone (1.0 g, 6.05 mmol) in methanol (4 ml). The reaction was stirred for 4h at r.t. The precipitate was filtered, washed with MeOH and dried in vacuo to provide chalcone **5a** as a white solid (1.2 g, 75% yield). The spectroscopic data are consistent with material from commercial sources. ^1H NMR (400 MHz, CDCl_3) δ 8.34 (d, J = 8.8 Hz, 2H), 8.13 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 15.6 Hz, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 15.6 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 189.2, 150.1, 147.0, 143.4, 142.1, 131.7, 130.0, 129.5, 128.9, 123.9, 120.4, 21.7.



(E)-1-(4-Nitrophenyl)-3-phenylprop-2-en-1-one (5b)


4-Nitroacetophenone (1.0 g, 6.05 mmol) and benzaldehyde (642 mg, 6.05 mmol) were dissolved in methanol (30 ml). An aqueous solution of sodium hydroxide (5 % w/v, 15 ml) was added slowly and the reaction mixture was stirred at room temperature for 12 h. The obtained solid was filtered, washed with water (15 ml) and crystallized from methanol to provide chalcone **5b** as a yellow solid (1.2 g, 80% yield). The spectroscopic data are consistent with material from commercial sources. ^1H NMR (400 MHz, CDCl_3) δ 8.36 (d, J = 8.8 Hz, 2H), 8.15 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 15.6 Hz, 1H), 7.67-7.65 (m, 2H), 7.51-7.45 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3) δ 189.2, 150.2, 146.9, 143.2, 134.4, 131.4, 129.5, 129.3, 128.8, 124.0, 121.4.



(E)-1-phenyl-3-(p-tolyl)prop-2-en-1-one (5c)


Acetophenone (2.0 g, 16.6 mmol) and *p*-tolualdehyde (2.0 g, 16.6 mmol) were dissolved in methanol (80 ml). An aqueous solution of sodium hydroxide (5 % w/v, 40 ml) was added slowly and the reaction mixture was stirred at room temperature for 12 h. The obtained solid was filtered, washed with water (15 ml) and crystallized from methanol to provide chalcone **5c** as a yellow solid (2.7 g, 73% yield). The spectroscopic data are consistent with previously

reported.¹ ¹H NMR (400 MHz, CDCl₃) δ 8.03-8.01 (m, 2H), 7.80 (d, *J* = 16.0 Hz, 1H), 7.61-7.48 (m, 6H), 7.23 (d, *J* = 8.0 Hz, 2H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 190.8, 145.1, 141.3, 138.5, 132.8, 132.3, 129.9, 128.7, 128.63, 128.62, 121.2, 21.7.




(2S,3R)-N-(3-Chlorophenyl)-1-(4-methoxyphenyl)-2-methyl-4-(4-nitrobenzoyl)-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (6a)

A solution of 4-anisidine (63 mg, 0.51 mmol), 4-tolualdehyde (123 mg, 1.02 mmol), pyruvic amide **3b** (200 mg, 1.02 mmol) and chalcone **5a** (272 mg, 1.02 mmol) in EtOH (19 ml) and HOAc (1.6 ml) was stirred under reflux for 8 h. After cooled down to r.t., ethanol was removed under vacuum, and the residue was diluted with EtOAc and water. After separation, the aqueous phase was extracted two more times with EtOAc. The combined organic phases were successively washed with saturated aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, concentrated *in vacuo* and chromatographed gradiently on silica gel with pentane/diethyl ether (5:1~1:1) to give the dihydropyrrole **6a** (80 mg, 23% yield) as a yellow solid, and **4b** (80 mg, 23% yield) as a yellow solid. **6a**: ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 8.4 Hz, 2H), 7.41 (d, *J* = 8.4 Hz, 2H), 7.21-7.18 (m, 2H), 7.06-7.02 (m, 3H), 6.92-6.85 (m, 7H), 6.70 (d, *J* = 7.2 Hz, 2H), 6.65 (d, *J* = 8.8 Hz, 2H), 4.95 (s, 1H), 3.69 (s, 3H), 2.23 (s, 3H), 2.08 (s, 3H), 1.70 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 189.0, 169.3, 162.8, 158.0, 148.0, 146.3, 140.2, 137.9, 137.8, 135.2, 134.4, 131.6, 130.4, 129.75, 129.73, 129.6, 129.1, 128.6, 127.9, 127.7, 125.0, 122.4, 121.0, 118.9, 114.7, 114.4, 77.7, 62.4, 55.4, 23.7, 21.3, 21.1. HRMS (ESI-TOF) *m/z* calcd. for C₄₀H₃₅N₃O₅Cl [M+H]⁺: 672.2260, found 672.2245.



(2S,3R)-N-(3-Chlorophenyl)-2-ethyl-1-(4-methoxyphenyl)-4-(4-nitrobenzoyl)-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (6b**)**


A solution of 4-anisidine (117 mg, 0.95 mmol), 4-tolualdehyde (114 mg, 0.95 mmol), pyruvic amide **3j** (200 mg, 0.95 mmol) and chalcone **5b** (240 mg, 0.95 mmol) in EtOH (38 ml) and HOAc (3.0 ml) was stirred under reflux for 8 h. After cooled down to r.t., ethanol was removed under vacuum, and the residue was diluted with EtOAc and water. After separation, the aqueous phase was extracted two more times with EtOAc. The combined organic phases were successively washed with saturated aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, concentrated *in vacuo* and chromatographed gradiently on silica gel with PE/EA (5:1~3:1) to give the dihydropyrrole product **6b** as a yellow solid (98 mg, 16% yield). ¹H NMR (400 MHz, CD₃OD) δ 7.76 (d, *J* = 8.4 Hz, 2H), 7.41-7.36 (m, 4H), 7.23-7.21 (m, 2H), 7.18-7.14 (m, 2H), 7.07-7.02 (m, 2H), 6.97 (d, *J* = 8.8 Hz, 3H), 6.89 (d, *J* = 7.6 Hz, 2H), 6.74-6.72 (m, 1H), 6.67 (d, *J* = 9.2 Hz, 3H), 5.16 (s, 1H), 3.66 (s, 3H), 2.52-2.46 (m, 1H), 2.16-2.09 (m, 1H), 2.05 (s, 3H), 1.16 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CD₃OD) δ 190.6, 170.9, 168.5, 159.5, 149.0, 148.2, 141.0, 140.1, 139.7, 134.7, 132.5, 130.6, 130.5, 130.4, 129.3, 129.22, 129.21, 129.18, 128.3, 125.9, 123.8, 123.37, 123.35, 121.9, 115.8, 114.8, 83.1, 57.5, 55.8, 27.2, 21.1, 8.6. HRMS (ESI-TOF) *m/z* calcd. for C₄₀H₃₅N₃O₅Cl [M+H]⁺: 672.2260, found 672.2262.



(2S,3R)-4-benzoyl-N-(4-chlorophenyl)-2-ethyl-1-(4-methoxyphenyl)-3,5-di-p-tolyl-2,3-dihydro-1H-pyrrole-2-carboxamide (6c)

A solution of *p*-anisidine (58 mg, 0.47 mmol), *p*-tolualdehyde (56 mg, 0.47 mmol), **3k** (100 mg, 0.47 mmol), and **5c** (105 mg, 0.47 mmol) in EtOH (9.2 ml) and HOAc (0.74 ml) was stirred under reflux for 8 h. After cooled down to r.t., ethanol was removed under vacuum, and the residue was diluted with ethyl acetate and water. After separation, the aqueous phase was extracted two more times with ethyl acetate. The combined organic phases were successively washed with saturated aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, concentrated *in vacuo* and chromatographed gradiently on silica gel with PE/EA (5:1~3:1) to give the dihydropyrrole product **6c** as a yellow solid (53 mg, 18% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (s, 1H), 7.31 (d, *J* = 7.2 Hz, 2H), 7.19 (d, *J* = 8.4 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 7.08 (t, *J* = 7.2 Hz, 2H), 6.96-6.93 (m, 5H), 6.90 (d, *J* = 8.4 Hz, 2H), 6.78 (d, *J* = 9.2 Hz, 2H), 6.70 (d, *J* = 7.2 Hz, 2H), 6.60 (d, *J* = 8.8 Hz, 2H), 5.26 (s, 1H), 3.68 (s, 3H), 2.37-2.21 (m, 1H), 2.19 (s, 3H), 3.12 (s, 3H), 2.09-2.03 (m, 1H), 1.07 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 192.1, 169.6, 160.4, 157.1, 140.4, 139.2, 137.0, 135.64, 135.61, 132.2, 130.3, 129.9, 129.7, 129.4, 128.9, 128.8, 128.5, 128.3, 128.1, 127.8, 127.3, 121.7, 114.8, 114.0, 80.3, 57.2, 55.4, 26.5, 21.3, 21.1, 8.3. HRMS (ESI-TOF) *m/z* calcd. for C₄₁H₃₈N₂O₃Cl [M+H]⁺: 641.2565, found 641.2558.

3. Mechanism studies




(E)-4-(4-methoxyphenyl)-1-phenyl-3-(p-tolyl)but-2-en-1-one (7)


Compound **7** was prepared following the known method².

To a solution of **5c** (1.3 g, 6.0 mmol) in anhydrous EtOH (3 ml) was added 4-methoxyaniline (1.1 g, 9.0 mmol) and K₃PO₄ (192 mg). After stirring for five hours at r.t., the reaction mixture was diluted with ethyl acetate and water. After separation, the aqueous phase was extracted two more times with ethyl acetate. The combined organic phase was washed with

brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product, which was purified by column chromatography on silica gel with PE/EA (50:1), the title compound was obtained (550 mg, 27% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 7.6 Hz, 2H), 7.56 (t, *J* = 7.2 Hz, 1H), 7.45 (t, *J* = 7.6 Hz, 2H), 7.33 (d, *J* = 3.6 Hz, 2H), 7.14 (d, *J* = 8.0 Hz, 2H), 6.69 (d, *J* = 8.8 Hz, 2H), 6.54 (d, *J* = 8.8 Hz, 2H), 4.91 (t, *J* = 7.2 Hz, 1H), 4.27 (s, 1H), 3.69 (s, 3H), 3.48 (dd, *J* = 5.2, 16.0 Hz, 1H), 3.39 (dd, *J* = 7.6, 16.0 Hz, 1H), 2.32 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 198.6, 152.4, 141.4, 140.4, 137.0, 136.9, 133.5, 129.6, 128.8, 128.3, 126.5, 115.5, 114.8, 55.8, 55.5, 46.6, 21.2. HRMS (ESI-TOF) *m/z* calcd. for C₂₃H₂₄NO₂ [M+H]⁺: 346.1802, found 346.1786.




Using *p*-tolualdehyde (49 mg, 0.41 mmol), **3a** (80 mg, 0.41 mmol), and **7** (140 mg, 0.41 mmol) in EtOH (8 ml) and HOAc (0.64 ml) was stirred under reflux for 8 h. After cooled down to r.t., ethanol was removed under vacuum, and the residue was diluted with ethyl acetate and water. After separation, the aqueous phase was extracted two more times with ethyl acetate. The combined organic phases were successively washed with saturated aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, concentrated *in vacuo* and chromatographed gradiently on silica gel with PE/EA 5:1~3:1 to give the dihydropyrrole product **4a** as a yellow solid (64 mg, 45%).




Using *p*-anisidine (31 mg, 0.25 mmol), *p*-tolualdehyde (60 mg, 0.5 mmol), and **3a** (100 mg, 0.5 mmol) in accordance with General Procedure B, the title compound was obtained (89 mg,

51% yield) as a yellow solid, and the aldol condensation product **5** was obtained (6 mg, 4% yield) as a yellow solid, along with unknown byproducts. Spectra data of the aldol product: ^1H NMR (400 MHz, CDCl_3) δ 9.03 (s, 1H), 8.01 (d, $J = 16.0$ Hz, 1H), 7.82 (d, $J = 16.0$ Hz, 1H), 7.66 (d, $J = 8.0$ Hz, 2H), 7.60 (d, $J = 7.2$ Hz, 2H), 7.35 (d, $J = 8.0$ Hz, 2H), 7.26-7.24 (m, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 185.2, 159.1, 149.4, 142.9, 135.4, 131.7, 130.4, 130.1, 129.6, 129.4, 121.1, 116.8, 21.8. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{17}\text{H}_{14}\text{ClNO}_2\text{Na} [\text{M}+\text{Na}]^+$: 322.0605, found 322.0602.




Using *p*-anisidine (58 mg, 0.47 mmol), **14b** (91 mg, 0.47 mmol), and **3k** (100 mg, 0.47 mmol), in accordance with General Procedure B, the title compound was obtained (45 mg, 19% yield) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.59 (s, 1H), 7.54 (d, $J = 8.4$ Hz, 2H), 7.30 (d, $J = 8.4$ Hz, 2H), 7.14 (d, $J = 8.0$ Hz, 2H), 6.98 (d, $J = 7.6$ Hz, 2H), 6.78 (d, $J = 8.4$ Hz, 2H), 6.61 (d, $J = 8.4$ Hz, 2H), 3.70-3.66 (m, 4H), 3.52 (d, $J = 16.4$ Hz, 1H), 2.26 (s, 3H), 2.07-2.02 (m, 1H), 1.89-1.83 (m, 1H), 1.06 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.8, 161.3, 159.0, 140.3, 136.7, 129.7, 129.6, 129.3, 129.0, 128.7, 125.9, 122.3, 121.4, 114.3, 75.7, 55.4, 36.9, 27.8, 21.7, 7.5. HRMS (ESI-TOF) m/z calcd. for $\text{C}_{27}\text{H}_{25}\text{N}_3\text{O}_4\text{Cl} [\text{M}-\text{H}]^-$: 490.1539, found 490.1535.




Using *p*-anisidine (58 mg, 0.47 mmol), **15** (130 mg, 0.47 mmol), and **3k** (100 mg, 0.47 mmol), in accordance with General Procedure B, the title compound was obtained (55 mg, 23% yield) as a yellow solid.


4. ORTEP Drawing for 4o



5. NOESY for 4a



The correlation between the methyl group and the proton was observed:



6. Kinetics of α -Glucosidase Inhibition

The commercially available α -glucosidase from baker's yeast (Sigma, G5003) was selected as the target protein using *p*-nitrophenyl- α -D-glucopyranoside (pNGP, Sigma, N1377) as the substrate. The compounds and acarbose were dissolved in DMSO. The enzyme and the substrate were dissolved in 0.05 M potassium phosphate buffer with pH 6.8. The enzymatic reaction mixture composed of 20 μ L α -glucosidase (0.03 U/ml), 30 μ L of substrate (0.6, 1.2, 2.4 mM), 10 μ L of test compounds (0, 0.62, 5 μ M) or acarbose (0, 0.19, 0.39 mM), and 140 μ L of potassium phosphate buffer was incubated at 37 $^{\circ}$ C for 20 min. The enzymatic activity was detected by spectrophotometer at the wavelength of 405 nm. The inhibitory kinetics of the investigated compounds on α -glucosidase was analyzed using the Lineweaver-Burk plot of the substrate concentration and velocity. Results are the average of three independent experiments, each performed in duplicate.





Fig. S1 Lineweaver-Burk plot of acarbose


7. Reference



1. Jin-Lin Zuo, Jia-Xiang Yang, Fu-ZhiWang, Xiang-Nan Dang, Jian-Liang Sun, De-Chun Zou, Yu-Peng Tian, Na Lin, Xu-Tang Tao, Min-Hua Jiang. *Journal of Photochemistry and Photobiology A: Chemistry*. **2008**, *199*, 322-329.
2. Barahman Movassagh, Sakineh Khosousi. *Monatshefte fuer Chemie*. **2012**, *143*, 1503-1506.


8. Spectra Data


Spectra data are shown from the next page.


















3d





Current Data Parameters
NAME LHM-A179-4c
EXPNO 1
PROCNO 1


F2 - Acquisition Parameters
Date_ 20161023
Time 15.12
INSTRUM spect
PROBHD 5 mm PABBO/BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 8
DS 2
CONE 9802.937 Hz
FIDRES 0.134230 Hz
AQ 3.7224448 sec
RG 193.38
SW 55.950 usec
DE 6.50 usec
TE 296.2 K
D1 1.0000000 sec
TD0 1


----- CHANNEL f1 -----
NUC1 400.1324710 MHz
P1 14.80 usec
PLW1 12.5000000 W


F2 - Processing parameters
SI 65536
SF 400.1330124 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00
















































Current Data Parameters
NAME L2N-A179-01
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20161201
Time 10.30
INSTRUM spect
PROBHD 5 mm QNP1H H
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 8
DS 2
SWH 8802.817 Hz
FIDRES 0.134320 Hz
AQ 1.7224448 sec
RG 191.28
DW 56.800 usec
DE 6.50 usec
TE 296.1 K
D1 1.0000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 400.1324710 MHz
P1 18
PL1 12.50000000 W

F2 - Processing parameters
SI 65536
SF 400.130918 MHz
WDW 0
SSB 0
LB 0.30 Hz
GB 0
PC 1.00








Current Data Parameters
NAME 12A-A379-156
EXPNO 1
PROCNO 1


F2 - Acquisition Parameters
Date_ 20170217
Time 15.31
INSTRUM spect
PROBHD 5 mm PASSED 2B-
PULPROG zgpg30
TD 65536
SOLVENT CHCl3
NS 8
DS 2
SWH 8802.817 Hz
FIDRES 0.134320 Hz
AQ 3.7224448 sec
RG 37.47
SW 66.850 csec
SB 6.50 csec
TB 291.1 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 400.1324710 MHz
P1 14.80 csec
PL1 12.50000000 W
F2 - Processing parameters
SI 65536
SF 400.1300142 MHz
WDW EM
SSB 0
GB 0 0.30 Hz
PC 1.00










3.697

2.275

2.096

1.652

0.004



4c





Current Data Parameters
 NAME 128-P-8
 EXPNO 1
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20141120
 Time_ 19.11
 INSTRUM spect
 PROBRD 5 mm BBO-2B-
 PULPROG zg30
 TD 65536
 SOLVENT CHCl3
 NS 8
 DS 2
 SWE 8802.817 Hz
 FIDRES 0.134320 Hz
 AQ 3.1224448 sec
 RG 131.57
 DM 56.820 usec
 DE 6.10 usec
 TE 295.0 K
 D1 1.00000000 sec
 TDS 1






----- CHANNEL f1 -----
 SFO1 400.1324710 MHz
 NUCL1 1H
 P1 14.80 usec
 PLW1 12.50000000 W

F2 - Processing parameters
 S1 65536
 SF 400.1300113 MHz
 WDW RM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00










Current Data Parameters
NAME 12A-P-7-MECH
EXPNO 1
PROCNO 1


F2 - Acquisition Parameters
Date_ 20170113
Time 10.53
INSTRUM spect
PROBHD 5 mm HARR-5B-
PULPROG zgpg30
TD 65536
SOLVENT MeOH
NS 8
DS 2
SWH 8802.857 Hz
FIDRES 0.134320 Hz
AQ 3.7224448 sec
RG 77.88
DM 64.800 cmec
DE 6.50 cmec
TE 298.1 K
D1 1.00000000 sec
TD0 1


----- CHANNEL f1 -----
SFO2 400.1324710 MHz
NUC1 1H
P1 14.80 cmec
PLA1 12.50000000 W


F2 - Processing parameters
SI 65536
SF 400.1300087 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00
































































































Current Data Parameters
NAME LSK-A179-72-1215
EXPNO 1
PROCNO 1


F2 - Acquisition Parameters
Date_ 20161215
Time 9.01
INSTRUM spect
PROBHD 5 mm HANCEV SB-
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 8
DS 2
SWH 8802.817 Hz
FIDRES 0.134320 Hz
AQ 3.7224448 sec
RG 192.38
SD 192.38
DM 64.800 usec
DE 6.50 usec
TE 294.7 K
D1 1.00000000 sec
TD0 1


===== CHANNEL f1 =====
NUC1 400.1324710 MHz
NUC2 1H
P1 14.80 usec
PLA1 12.50000000 W


F2 - Processing parameters
SI 65536
SF 400.1300124 MHz
WDW RM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

















Current Data Parameters
NAME 128-A155-36-2-0110
EXPNO 1
PROCNO 1


F2 - Acquisition Parameters
Date_ 20170110
Time 9.46
INSTRUM spect
PROBHD 5 mm BBO-5-1H-1
PULPROG zg30
TD 65536
SOLVENT MeCl
NS 8
DS 2
SFO2 8802.817 Hz
FIDRES 0.134320 Hz
AQ 2.1224448 sec
RG 110.63
DM 64.800 usec
DE 6.50 usec
TE 298.2 K
D1 1.00000000 sec
V2 1


===== CHANNEL f1 =====
NUC1 1H
P1 14.80 usec
PLW1 12.50000000 W

F2 - Processing parameters
SI 65536
SF 400.1300982 MHz
WDW EM
SSB 0
GB 0 0.30 Hz
PC 1.00









```

Current Data Parameters
NAME      LIA-A179-162-C
EXPNO     2
PROCNO    1

F2 - Acquisition Parameters
Date_     20170518
Time      15.05
INSTRUM   spect
PROBHD    5 mm PABBO HB-
PULPROG   zgpg30
TD        65536
SOLVENT   CDCl3
NS         157
DS         4
SWH        24038.461 Hz
FIDRES     0.364798 Hz
AQ         1.3631488 sec
RG         193.28
DM         20.800 umsec
DE         6.50 umsec
TE         299.2 K
D1         2.0000000 sec
D11        0.0300000 sec
TD0        1

===== CHANNEL f1 =====
SP01      100.6228293 MHz
NUC1       13C
P1         12.00 umsec
PLW1       42.63700104 W

===== CHANNEL f2 =====
SP02      400.1314005 MHz
NUC2       1H
CHRGPG2    waltz16
PCPG2      80.00 umsec
PLW2       12.50000000 W
PLW12      0.42781001 W
PLW13      0.27379999 W

F2 - Processing parameters
SI         32768
SF         100.6127592 MHz
WDW        RM
SSB         0
LB          1.00 Hz
GB          0
PC          1.40

```

